Molecule glue drugs shake up cancer care, draw big money

▤ Summary

Molecular glue drugs are emerging as a major new approach in cancer treatment, especially for hard-to-target proteins. Revolution Medicines reported encouraging late-stage pancreatic cancer results that could double typical survival time. The success has drawn major pharma partners and investors, with companies like Novartis, Roche, and Eli Lilly signing big research deals. Several biotech rivals are also racing to develop similar therapies, and the competitive momentum has pushed valuations and share prices higher.

▦ Linked Companies

Roche

$1B+